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We have shown that osteopontin (OPN), an extracellular matrix protein, plays an important role in post
myocardial infarction (MI) remodeling by promoting
collagen synthesis and accumulation. Interleukin-1␤
(IL-1␤), increased in the heart following MI, increases
matrix metalloproteinase (MMP) activity in cardiac fibroblasts in vitro. Here, we show that OPN alone has no
effect on MMP activity or expression. However, it reduces IL-1␤-stimulated increases in MMP activity and
expression in adult rat cardiac fibroblasts. Pretreatment with bovine serum albumin had no effect on MMP
activity or protein content, whereas GRGDS (glycinearginine-glycine-aspartic acid-serine)-pentapeptide
(which interrupts binding of RGD-containing proteins
to cell surface integrins) and monoclonal antibody m7E3
(a rat ␤3 integrins antagonist) inhibited the effects of
OPN. Inhibition of PKC using chelerythrine inhibited
the activities of both MMP-2 and MMP-9. Stimulation of
cells using IL-1␤ increased phosphorylation and translocation of PKC to membrane fractions, which was inhibited by OPN. OPN inhibited IL-1␤-stimulated increases in translocation of PKC- from cytosolic to
membrane fractions. Furthermore, the levels of phospho-PKC- were lower in the cytosolic fractions of OPN
knock-out mice hearts as compared with wild type 6
days post-MI. Inhibition of PKC-  using PKC- 
pseudosubstrate inhibited IL-1␤-stimulated increases in
MMP-2 and MMP-9 activities. These observations suggest that OPN, acting via ␤3 integrins, inhibits IL-1␤stimulated increases in MMP-2 and MMP-9 activity, at
least in part, via the involvement of PKC-. Thus, OPN
may play a key role in collagen deposition during myocardial remodeling following MI by modulating cytokine-stimulated MMP activity.

The dynamic synthesis and breakdown of extracellular matrix (ECM)1 proteins may play an important role in myocardial
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remodeling (1, 2). Osteopontin (OPN) is a glycosylated and
phosphorylated ECM protein (3, 4). Although first isolated
from mineralized matrix, OPN has since been shown to be
synthesized by cardiac fibroblasts, endothelial cells, and myocytes (3, 5–7). Using spontaneously hypertensive and aorticbanded rats, we have shown increased expression of OPN coincident with heart failure (8). OPN interacts with specific
integrins, namely ␣v␤1, ␣v␤3, ␣v␤5, and also with CD44 receptors and affects many cellular processes including cell attachment, spreading, and migration (3, 4, 9). Recently, we have
documented an increased expression of OPN in remote and
infarct regions of left ventricle following myocardial infarction
(MI). Furthermore, using OPN knock-out mice and MI as a
model of myocardial remodeling, we demonstrated that a lack
of OPN results in greater left ventricle dilation and reduced
collagen synthesis and accumulation 1 month post-MI, suggesting a role for OPN in ECM reorganization in the heart during
myocardial remodeling (10). A critical role for OPN in the
generation of interstitial fibrosis was observed in the skin
incision model of wound healing and in the kidney following
obstructive uropathy (11, 12). OPN has been shown to modulate the activity of matrix metalloproteinases (MMPs) in various cell types (13–15).
MMPs are a large family of zinc-containing endoproteinases
involved in degradation of ECM components (1, 16 –19).
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are well
known for their ability to degrade gelatin and type IV collagen.
Because of their ability to initiate and continue the degradation
of fibrillar collagens, the gelatinases are considered to play a
major role in the remodeling of collagenous ECM (19). Since
MMPs are capable of degrading ECM, the activity of these
enzymes is under strict regulation. Within the heart, MMPs
are synthesized by fibroblasts, inflammatory cells, and cardiac
myocytes (19, 20). Normal heart expresses low basal levels of
MMPs. Increased expression and activity of MMP-1, MMP-2,
MMP-3, and MMP-9 have been demonstrated in human, rat,
and porcine hearts during the remodeling process following MI
(21–23). Proinflammatory cytokines such as interleukin-1␤ (IL1␤) and tumor necrosis factor-␣ are increased in the heart
following MI (24, 25). Recently, using in vitro cultures of cardiac fibroblasts, Siwik et al. (26) demonstrated that IL-1␤ and
tumor necrosis factor-␣ increase MMP-2 and MMP-9 expression and activities. However, signaling pathways involved in
the regulation of MMP expression and activity have not yet
been clarified. In cells of non-cardiac origin, activation of protein kinase C (PKC) is suggested to play a critical role in the
IL-1␤, interleukin-1␤; PKC, protein kinase C; BSA, bovine serum albumin; KO, knock-out; WT, wild type; ANOVA, analysis of variance.
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regulation of expression and activity of MMPs (27). Among the
PKC isoforms, the activation of PKC- (atypical isoform) is
shown to be essential for MMP-1, MMP-3, and MMP-9 secretion in rabbit smooth muscle cells (28).
Since both OPN and IL-1␤ are increased during pathophysiological conditions of the heart, we hypothesized that OPN
increases collagen accumulation in the heart following MI by
inhibiting IL-1␤-stimulated MMP activity. The data presented
here suggest that OPN inhibits IL-1␤-stimulated increases in
MMP-2 and MMP-9 activity via the involvement of PKC-.
EXPERIMENTAL PROCEDURES

Rat Cardiac Fibroblasts Culture and Treatments—Adult rat cardiac
fibroblasts were isolated from the supernatant of adult rat cardiac
myocytes as described previously (26). The cells were grown to confluence and serum-starved for 48 h before use. Cells from the first and
second passages were used for all of the experiments. The cells were
treated with IL-1␤ (4 ng/ml) for 48 h to measure MMP activity or for
15–30 min to measure activation and translocation of PKC and PKC-.
OPN (50 –200 nM, purchased from R&D systems), bovine serum albumin (BSA, 100 nM), GRGDS-pentapeptide (100 nM), or monoclonal antibody m7E3 F(ab⬘)2 (m7E3, 40 –160 g/ml) was added 30 min prior to
the addition of IL-1␤. The ␤3 integrin antagonist m7E3, kindly received
from Dr. Robert Jordan (Centocor), binds rat ␤3 integrins and has been
shown to inhibit MMP activity and smooth muscle cell migration (29).
For experiments testing the role of PKC, cells were pretreated with
chelerythrine (1–5 M) or PKC- pseudosubstrate (50 M) for 30 min
followed by treatment with IL-1␤ for 48 h.
In-gel Zymography—MMP activity in the conditioned media of fibroblasts was measured as described previously (26). The media were
collected, centrifuged for 5 min at 500 ⫻ g to remove cells and debris,
and lyophilized to dryness. The pellet was resuspended in water, and
protein content was determined using Bradford assay (Bio-Rad). Samples (500 ng of protein) were loaded under non-reducing conditions onto
4% stacking and 10% separating SDS-polyacrylamide gel polymerized
with 1 mg/1 ml gelatin (type A from porcine skin, Sigma) as a substrate
and electrophoresed at 15–20 mA. Following electrophoresis, the gels
were washed in 2.5% Triton X-100 for 30 min with gentle shaking
followed by a 30-min wash in distilled water. The gels were then
incubated overnight at 37 °C in substrate buffer (50 mM Tris-HCl, pH 8,
5 mM CaCl2, and 0.02% NaN3), stained with Coomassie Blue R-250, and
then destained using 7% acetic acid and 40% methanol solution. Clear
and digested regions representing MMP activity were quantified using
an imaging densitometry (GS 700, Bio-Rad), and molecular weights
were estimated using prestained molecular weight markers.
Western Blot Analyses—Activation of PKC and PKC- was studied
using Western analyses. Total cell lysates were prepared in lysis buffer
(1% Triton X-100, 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM
EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium orthovanadate, and 0.5% Nonidet P-40), and protein contents were measured using the Bradford assay. Cytosolic and membrane fractions were
prepared as described previously (30). Cells were washed with cold
phosphate-buffered saline and incubated in hypotonic buffer (10 mM
Tris, pH 7.4, 0.5 mM EDTA, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin) on ice for 20 min. The cells were lysed using Dounce homogenization. The lysates were centrifuged at 40,000 rpm for 30 min. The
collected supernatant was considered a cytosolic fraction. The pellet
containing membranes was resuspended in the hypotonic buffer containing 1% Triton X-100 and centrifuged again at 30,000 ⫻ g for 30 min.
The supernatant was collected as membrane fraction. Equal amounts of
proteins (30 g) from total cell lysate, cytosolic fractions, or membrane
fractions were resolved by 10% SDS-PAGE, and proteins were transferred to polyvinylidene difluoride membranes. The membranes were
then probed with anti-phospho-PKC (pan) or anti-phospho-PKC- (Thr410, Cell Signaling Technology) antibodies. Anti-phospho-PKC(pan)antibodies used in Western blot recognize ␣, ␤I, ␤II, , ⑀, , and ␦ isoforms.
The membranes were then incubated with appropriate secondary antibodies and analyzed as described previously (5, 6, 31). Protein expression of MMP-2 and MMP-9 was measured in the conditioned media
using monoclonal MMP-2 or MMP-9 antibodies.
RNA Isolation and Northern Analysis—Total RNA from cells was
extracted using the method of Chomczynski and Sacchi (32). RNA was
size-fractionated on 1.0% formaldehyde-agarose gel and transferred to
Genescreen plus membrane. The blots were hybridized overnight using
MMP-2 cDNA as probe as described previously (8). The loading of RNA
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in each lane was observed from ethidium bromide-stained gels.
Myocardial Infarction and Preparation of Tissue Extracts—MI was
performed on age-matched OPN knock-out (KO) and wild-type (WT)
mice as described previously (10). The sham animals underwent the
same procedure without ligation of the coronary artery. All of the
experiments were performed in accordance with protocols approved by
the Institutional Animal Care and Use Committee. The mice were
sacrificed 6 days post-MI. To prepare cytosolic fractions, tissue from
non-infarcted left ventricle region was homogenized in lysis buffer (50
mM Tris-HCl, pH 7.6, 0.2 M NaCl, 5 mM CaCl2, 0.02% Brij-35, and 0.02%
NaN3) using glass homogenizer as described previously (33). The samples were centrifuged at 4 °C for 5 min at 2,500 rpm. The supernatant
was centrifuged again at 100,000 ⫻ g for 60 min. The supernatant was
collected as cytosolic fraction and analyzed by Western blot using antiphospho-PKC- antibodies. The membrane was then deprobed and reprobed with anti-PKC- (total) antibodies. To prepare total heart lysate,
tissue from non-infarcted left ventricle region was homogenized in lysis
buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA,
1 mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium
orthovanadate, and 0.5% Nonidet P-40). The samples were vortexed
and centrifuged at 12,000 rpm for 10 min. Equal amounts of proteins
from the supernatant were analyzed by Western blot using anti-phospho PKC- and anti-PKC- antibodies.
Statistical Analyses—All of the data are expressed as the mean ⫾
S.E. Statistical analysis was performed using the Student’s t test or a
one-way analysis of variance (ANOVA) and a post hoc Tukey’s test.
Probability (p) values of ⬍0.05 were considered to be significant.
RESULTS

OPN Inhibits IL-1␤-stimulated Increases in MMP Activity—
In-gel zymography of conditioned media from cardiac fibroblasts showed that IL-1␤ significantly increases MMP activity,
confirming our previous finding (26). Treatment of cells with
OPN in the presence of IL-1␤ dose dependently inhibited IL1␤-stimulated increases in MMP activity (Fig. 1A). The inhibition in MMP activity was detectable at 50 nM concentration of
OPN; however, it was significant at 100 nM. Therefore, a 100 nM
concentration was used for further experiments. Treatment of
cells with OPN inhibited IL-1␤-stimulated (folds change versus
control) MMP-2 (bands corresponding to 72/66 kDa; IL-1␤,
1.8 ⫾ 0.1; IL-1␤⫹OPN, 1.48 ⫾ 0.1; p ⬍ 0.001, n ⫽ 12) and
MMP-9 (bands corresponding to 95/88 kDa; IL-1␤, 3.7 ⫾ 0.4;
IL-1␤⫹OPN, 1.4 ⫾ 0.4; p ⬍ 0.001, n ⫽ 12) activities. OPN alone
had no effect on MMP activity. To confirm that the above
observations are specific for OPN, cardiac fibroblasts were pretreated with BSA (100 nM) followed by treatment with IL-1␤ for
48 h. An analysis of conditioned media showed that pretreatment of cells with BSA did not significantly affect MMP-2
(IL-1␤, 1.8 ⫾ 0.1; IL-1␤⫹BSA, 1.9 ⫾ 0.2) and MMP-9 (IL-1␤,
3.7 ⫾ 0.4; IL-1␤⫹BSA, 3.5 ⫾ 0.2; see Fig. 1) activities.
Western blot analyses of the conditioned media demonstrated that IL-1␤ increases MMP-2 (Fig. 2A) and MMP-9 (Fig.
2B) protein contents by 7.9 ⫾ 0.01- and 10.2 ⫾ 1.7-folds, respectively. Pretreatment with OPN reduced MMP-2 and
MMP-9 protein levels 0.8 ⫾ 0.1- and 1.0 ⫾ 0.1-folds (p ⬍ 0.05
versus IL-1␤), respectively. Pretreatment with BSA had no
significant effect on IL-1␤-mediated increases in MMP2 and
MMP-9 protein contents.
Northern analysis of RNA using MMP-2 cDNA as a probe
demonstrated increased expression of MMP-2 following 48 h of
IL-1␤ stimulation. This increase in MMP-2 mRNA was inhibited by pretreatment with OPN (Fig. 2C).
OPN contains an arginine-glycine-aspartate (RGD) cell binding domain (3, 4, 9) and interacts with integrin and CD44
receptors. Therefore, to study the receptor-mediated effects of
OPN, cells were pretreated with GRGDS-pentapeptide (100
nM). An analysis of conditioned media showed that pretreatment with GRGDS-pentapeptide significantly inhibits OPNmediated decreases in MMP-2 (IL-1␤, 2.0 ⫾ 0.1; IL-1␤⫹OPN,
1.3 ⫾ 0.1; RGD⫹IL-1␤⫹OPN, 1.7 ⫾ 0.1-folds) and MMP-9
(IL-1␤, 3.5 ⫾ 0.3; IL-1␤⫹OPN, 1.7 ⫾ 0.1; RGD⫹IL-1␤⫹OPN,
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FIG. 1. OPN inhibits IL-1␤-stimulated MMP activity. Confluent cultures
of cardiac fibroblasts were pretreated
with OPN (50 –200 nM) (A), OPN (100 nM)
or BSA (100 nM) (B) for 30 min followed by
treatment with IL-1␤ (4 ng/ml) for 48 h.
MMP activity in conditioned media was
measured using in-gel zymography. C and
D represent MMP-2 and MMP-9 activities, respectively, expressed as fold increase versus control (CTL). *, p ⬍ 0.001
versus CTL; #, p ⬍ 0.01 versus IL-1␤;
n ⫽ 12.

FIG. 2. OPN inhibits IL-1␤-stimulated MMP protein and mRNA
expression. Confluent cultures of cardiac fibroblasts were pretreated
with OPN (100 nM) or BSA (100 nM) for 30 min followed by treatment
with IL-1␤ (4 ng/ml) for 48 h. MMP-2 (A) and MMP-9 (B) protein levels
in the conditioned media were analyzed by Western blotting using
monoclonal anti-MMP-2 and anti-MMP-9 antibodies. The experiment
was repeated three times with similar results. C, total cellular RNAs
were analyzed by Northern analysis using MMP-2 cDNA probe. Pretreatment of cells with OPN prevents IL-1␤-stimulated increases in
MMP-2 mRNA (upper panel). Ethidium bromide-stained 18 S rRNA
(lower panel) is used to show the differences in loading. CTL, control.

3.2 ⫾ 0.3-folds) activities (Fig. 3). Similarly, OPN-mediated reduction in MMP-2 and MMP-9 protein levels in the conditioned
media was inhibited by pretreatment with GRGDS-pentapeptide
(data not shown), suggesting involvement of receptor-mediated
signaling in OPN-stimulated regulation of MMP activity.
To study the involvement of ␤3 integrins in OPN signaling,

cells were pretreated with 40 –160 g/ml m7E3 in the presence
of OPN for 30 min followed by treatment with IL-1␤ for 48 h.
m7E3 dose dependently inhibited OPN-mediated decreases in
MMP-2 and MMP-9 activity (data not shown). m7E3 at 160
g/ml concentration almost completely inhibited the effects of
OPN (Fig. 4, lane 5). To demonstrate that the effects of m7E3
are specific, cells were pretreated with BSA (160 g/ml) in the
presence of OPN (Fig. 4, lane 4).
Activation of PKC and Its Role in the Regulation of MMP
Activity—To elucidate the role of PKC in IL-1␤-stimulated
increases in MMP activity, activation of PKC was measured in
total cell lysates and membrane fractions using anti-phosphoPKC (pan) antibodies. Western analyses showed that IL-1␤
stimulation increases phosphorylation of PKC in total cell lysate (1.5 ⫾ 0.1-fold versus CTL, p ⬍ 0.05, n ⫽ 3; Fig. 5, A and
C) and membrane fractions (1.8 ⫾ 0.05-fold versus CTL, p ⬍
0.05, n ⫽ 3; Fig. 5, B and D). Pretreatment with OPN inhibited
the IL-1␤-stimulated increases in PKC activity in the lysate as
well as in membrane fractions.
To assess whether activation of PKC plays a role in the
regulation of IL-1␤-mediated increases in MMP activity, cells
were pretreated with chelerythrine (1 and 5 M, an inhibitor of
PKC). An analysis of conditioned media using in-gel zymography demonstrated that chelerythrine inhibits MMP activity
(MMP-2 and MMP-9) in a dose-dependent manner where 1 M
partially inhibits MMP activity and a 5 M concentration almost completely inhibits IL-1␤-stimulated increases in MMP
activity (Fig. 6).
Role of PKC- in the Regulation of MMP Activity—PKC-, an
atypical isoform, has been suggested to play a critical role in
the regulation of MMP activity in glioma cells and smooth
muscle cells (28, 34). In smooth muscle cells, PKC- is shown to
be essential for secretion of cytokine-induced MMP-1, MMP-3,
and MMP-9 (28). To elucidate the role of PKC-, we measured
phosphorylated PKC- in the cytosolic and membrane fractions
using anti-phospho-PKC- antibodies. Western analyses

Osteopontin Regulates MMP Activity in Cardiac Fibroblasts

48549

FIG. 3. GRGDS-pentapeptide inhibits the effects of OPN on IL-1␤-stimulated increases in MMP activity. Confluent cultures of cardiac fibroblasts were
pretreated with GRGDS-pentapeptide
(RGD, 100 nM) for 30 min followed by
treatment with OPN protein (100 nM) for
30 min. The cells then were stimulated
with IL-1␤ (4 ng/ml) for 48 h. MMP activity in conditioned media was measured
using in-gel zymography. Panel A represents zymography demonstrating the
changes in MMP activity. Panels B and C
represent MMP-2 and MMP-9 activities,
respectively, expressed as fold increase
versus control (CTL). *, p ⬍ 0.001 versus
CTL; #, p ⬍ 0.01 versus IL-1␤; @, p ⬍ 0.05
versus IL-1␤⫹OPN (n ⫽ 4).

peptide. This peptide has been shown to inhibit PKC- activity
by interacting with the substrate binding pocket in the catalytic domain (35, 36). An analysis of conditioned media using
in-gel zymography demonstrated that PKC- pseudosubstrate
inhibits MMP activity (Fig. 8).
DISCUSSION

FIG. 4. ␤3 integrin antagonist m7E3 inhibits the effects of OPN
on IL-1␤-stimulated increases in MMP activity. Confluent cultures
of cardiac fibroblasts were pretreated with m7E3 (160 g/ml) or BSA
(160 g/ml) for 30 min followed by treatment with OPN protein (100 nM)
for 30 min. The cells were then stimulated with IL-1␤ (4 ng/ml) for 48 h.
MMP activity in conditioned media was measured using in-gel
zymography.

showed that under basal (control) conditions, phosphorylated
PKC- is mainly present in the cytosolic fraction, not in the
membrane fraction. IL-1␤ stimulation increases phosphorylated PKC- in the membrane fractions while reducing the
amount of phosphorylated PKC- in the cytosolic fractions (Fig
7A). OPN inhibited IL-1␤-stimulated translocation of PKC-
from cytosolic fractions to membrane fractions. OPN alone had
no effect on PKC- translocation.
An analysis of cytosolic fractions of hearts 6 days post-MI
demonstrated higher levels of phosphorylated PKC- in WT MI
hearts as compared with WT sham and OPN KO MI hearts
(Fig. 7B, fold change, WT sham 1.0 ⫾ 0.16, n ⫽ 4; WT MI 1.8 ⫾
0.04*, n ⫽ 5; KO sham 0.9 ⫾ 0.3, n ⫽ 3; KO MI 1.2 ⫾ 0.09#, n ⫽
3; *, p ⬍ 0.01 versus WT sham; #, p ⬍ 0.01 versus WT MI). Total
heart lysates exhibited no apparent differences in the levels of
phosphorylated PKC- among these groups (data not shown).
To assess whether activation of PKC- plays a role in the
regulation of IL-1␤-mediated increases in MMP activity, cells
were pretreated with myristoylated PKC- pseudosubstrate

Previously, we have shown that increased expression of OPN
in the heart plays an important role in post-MI remodeling by
promoting collagen synthesis and accumulation (10). The major
new findings of this study are that OPN inhibits IL-1␤-stimulated increases in MMP activity (MMP-2 and MMP-9) and
expression in adult rat cardiac fibroblasts. OPN inhibits IL-1␤stimulated increases in PKC activity, specifically PKC- activity, and inhibition of PKC- activity inhibits IL-1␤-stimulated
increases in MMP activity.
The finding that OPN inhibits IL-1␤-stimulated increases in
MMP activity in adult rat cardiac fibroblasts is consistent with
the evidence that OPN plays a role in the regulation of ECM
remodeling (13–15). However, the inhibitory effects of OPN on
MMP activity were observed only in the presence of IL-1␤.
Purified recombinant OPN protein (purchased from R & D
systems) alone did not affect MMP-2 activity. Occasionally, we
observed increased MMP-9 activity; however, the data were not
found statistically significant. In human melanoma cells, recombinant OPN alone also failed to increase MMP-2 activity
(37). In human aortic smooth muscle cells, purified OPN alone
failed to affect MMP-2 or MMP-9 activity. However, OPN in the
presence of platelet-derived growth factor increased MMP-9
but not MMP-2 activity (13). In contrast, purified human milk
OPN protein alone increased MMP-2 production in murine
melanoma cells (15). The differential effects of OPN on MMP
activity in different cell types may reflect differences in the
kinetics of coupling to different OPN receptors in different cell
types. It is also important to emphasize that effects of OPN on
MMP-2 in murine melanoma cells were observed at 5–10 M,
whereas in cardiac fibroblasts and aortic smooth muscle cells,
the effects were observed at a 50 –100 nM concentration.
The effects of OPN on MMP-2 and MMP-9 activity seem to be
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FIG. 5. OPN inhibits IL-1␤-stimulated increases in PKC phosphorylation. Confluent cultures of cardiac fibroblasts were pretreated with OPN (100 nM)
for 30 min followed by treatment with
IL-1␤ for 15 min. Total cell lysates or
membrane fractions were prepared as described under “Experimental Procedures.” PKC activation was studied by
Western blot analyses using anti-phospho-PKC (pan) antibodies. Panels A and
B are representative blots obtained from
total cell lysates and membrane fractions,
respectively. Panels C and D exhibit PKC
phosphorylation expressed as fold increase versus control. *, p ⬍ 0.001 versus
CTL; #, p ⬍ 0.05 versus IL-1␤ (n ⫽ 4).

FIG. 6. Inhibition of PKC inhibits IL-␤-stimulated increases in
MMP activity. Confluent cultures of cardiac fibroblasts were pretreated with chelerythrine (Che; 1 and 5 M) for 30 min followed by
treatment with IL-1␤ for 48 h. MMP activity in the conditioned media
was measured using in-gel zymography.

specific since the same concentration of BSA (100 nM) had no
effect on IL-1␤-stimulated MMP activity. Furthermore, the
inhibitory effects of OPN were inhibited by GRGDS-pentapeptide and m7E3. GRGDS-pentapeptide alone had no effect on
MMP-2 or MMP-9 activities. Consistent with our findings,
Philip et al. (15) observed that RGD-containing non-cyclic and
cyclic (GRGDSP and GPenGRDSPCA)-peptides had no effect
on MMP-2 production and activation in murine melanoma
cells. OPN contains an RGD cell binding sequence and has been
shown to interact with ␣v␤3, ␣v␤5, ␣v␤1, and CD44 family of
receptors (3, 7, 9). Adult cardiac fibroblasts express ␣v, ␤1, ␤3,
and ␤5 integrins in vitro (38). Integrins and CD44 receptor
signaling are known to modulate MMP expression and activity
in various cell types (13, 39, 40). Using m7E3, an antagonist of
rat ␤3 integrins, we identify ␤3 integrins as a potential candidate involved in OPN signaling in cardiac fibroblasts. The
importance of ␤3 integrins, specifically ␣v␤3, in the regulation
of MMPs has been suggested in various cell types. In smooth
muscle cells, OPN binding to the ␣v␤3 receptors is shown to
stimulate MMP-9 and MMP-1 synthesis (13). Treatment with
m7E3 inhibited MMP-2 and MMP-9 activity in carotid extracts
obtained from Sprague-Dawley rats 4 days after balloon catheter injury, suggesting a role for ␣v␤3 integrins in the regulation of MMPs activity (29). In fact, ␣v␤3 integrins play an
important role in angiogenesis by binding and activating
MMP-2 in endothelial cells (41).
MMP activity is regulated by both transcriptional and posttranslational mechanisms (18, 19). Posttranslational regula-

tion of MMPs occurs through the activation of latent proenzymes (ProMMPs) by plasmin, trypsin, chymase, elastase, and
kallikrein. The membrane-type 1 MMP enzyme is also involved
in the activation of MMPs. Conversely, MMP activity can be
inhibited by interaction with naturally occurring inhibitors
called tissue inhibitors of MMPs. In a previous study, Siwik et
al. (26) provided evidence that IL-1␤ increases MMP activity
because of increased mRNA and protein expression in cardiac
fibroblasts. In this study, we provide evidence that OPN inhibits IL-1␤-stimulated activity of MMPs, at least in part, by
inhibiting their expression. IL-1␤-stimulated increases in both
MMP-2 and MMP-9 protein levels were inhibited by OPN.
Furthermore, IL-1␤-stimulated increases in MMP-2 mRNA
levels were also inhibited by pretreatment with OPN.
Expression of MMPs is normally low in adult heart tissue.
The MMP expression is up-regulated during certain physiological and pathological remodeling processes of the heart (17, 19,
42, 43). Once activated, MMPs are collectively capable of degrading the complete ECM. Therefore, it is important that the
activity of these enzymes is kept under tight control. In noncardiac fibroblasts and tumor cell lines, activation of PKC in
response to proinflammatory cytokines has been suggested to
be necessary for the expression and activation of MMPs (27, 28,
44, 45). In this study, using PKC inhibitor chelerythrine, we
show that activation of PKC plays a pivotal role in the regulation of IL-1␤-stimulated MMP activity in cardiac fibroblasts.
Chelerythrine represents a unique class of PKC inhibitors that
competitively interfere with the phosphate acceptor site and
non-competitively inhibit the ATP binding site (46). The inhibition of IL-1␤-stimulated PKC activation by OPN provides
indirect evidence that OPN may act through PKC to inhibit
IL-1␤-stimulated increase in MMP activity. PKC has been suggested to play an important role in OPN-induced migration of
human mammary epithelial cells (47)
In this study, we identify PKC- as a key regulator of IL-1␤stimulated MMP activity in adult rat cardiac fibroblasts. This
is evident from the data that stimulation of cells with IL-1␤
increases translocation of phosphorylated PKC- from cytosolic
fractions to membrane fractions. IL-1␤-stimulated translocation of PKC- is inhibited by OPN pretreatment. Furthermore,
the levels of phosphorylated PKC- were lower in the cytosolic
fractions of OPN KO hearts as compared with WT 6 days
post-MI, suggesting increased translocation of PKC- to membrane fractions in the absence of OPN in the heart post-MI. In

Osteopontin Regulates MMP Activity in Cardiac Fibroblasts

48551

FIG. 8. Inhibition of PKC- inhibits IL-1␤-stimulated increases
in MMP activity. Confluent cultures of cardiac fibroblasts were pretreated with PKC- pseudosubstrate (PS-zeta; 50 M) for 30 min followed by treatment with IL-1␤ for 48 h. MMP activity in the conditioned
media was measured using in-gel zymography. The experiment was
repeated three times with similar results.

adult rat cardiac fibroblasts, possibly through the inhibition of
PKC- pathway. Activation of PKC- plays a critical role in the
regulation of both MMP-2 and MMP-9 activity. Our findings of
inhibition of IL-1␤-stimulated MMP activity by OPN are consistent with the evidence that OPN plays an important role in
collagen accumulation and suggest that one mechanism, by
which OPN may promote collagen accumulation in the heart
following MI, is by inhibiting cytokine-stimulated increases in
MMP activity, possibly through the involvement of PKC-.
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